The effects of virgin coconut oil (VCO) as supplementation on quality of life (QOL) among breast cancer patients

  • Kim Sooi Law1Email author,

    Affiliated with

    • Nizuwan Azman1,

      Affiliated with

      • Eshaifol Azam Omar1,

        Affiliated with

        • Muhammad Yusri Musa1,

          Affiliated with

          • Narazah Mohd Yusoff1,

            Affiliated with

            • Siti Amrah Sulaiman2 and

              Affiliated with

              • Nik Hazlina Nik Hussain2

                Affiliated with

                Lipids in Health and Disease201413:139

                DOI: 10.1186/1476-511X-13-139

                Received: 8 April 2014

                Accepted: 23 August 2014

                Published: 27 August 2014

                Abstract

                Background

                Breast cancer is the most common cancer amongst Malaysian women. Both the disease and its treatment can disrupt the lives of the woman and adversely affect all aspects of life and thus can alter a woman’s quality of life. The aim of this study was to examine the effect of virgin coconut oil (VCO) on the quality of life (QOL) of patients diagnosed with breast cancer.

                Methods

                This was a prospective study of breast cancer patients admitted into the Oncology Unit of Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. The sample consisted of 60 patients with stage III and IV breast cancer allocated to either an intervention group (n = 30) or a control group (n = 30) using a simple random table. QOL was evaluated from the first cycle of chemotherapy to the sixth cycle, and data were collected using a validated Bahasa Malaysia version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-C30) and its breast-specific module (QLQ-BR 23).

                Results

                The mean age of breast cancer patients was 50.2 (SD = 13.5) years. There were significant mean score differences for functioning and global QOL between groups (α < 0.01). The intervention group also had better scores for symptoms including fatigue, dyspnea, sleep difficulties, and loss of appetite compared to the control group. Although there are deteriorations for sexual enjoyment, the intervention group exhibited improvement in breast functioning and symptom scores for body image, sexual function, future perspective, breast symptoms, and systemic therapy side effects.

                Conclusion

                VCO consumption during chemotherapy helped improve the functional status and global QOL of breast cancer patients. In addition, it reduced the symptoms related to side effects of chemotherapy.

                Keywords

                Virgin coconut oil (VCO) Quality of life (QOL) Breast cancer patient Chemotherapy

                Background

                In Malaysia, breast cancer is the most common cancer that affects women and rated as the main cause of mortality, among other cancers[1]. According to the third report of the National Cancer Registry (2003–2005), the incidence of breast cancer among women in Malaysia is 31.3%. The high mortality rate of breast cancer also contributed to the 15.2% of medically certified death due to cancer[2].

                Chemotherapy and radiotherapy are commonly used after primary treatment of breast cancer to inhibit metastasis and enhance long-term survival rates[36]. However chemotherapy often is associated with many negative side effects such as nausea and vomiting, hair loss, fatigue, pain, anxiety, depression and others[79]. Most of the side effects were perceived by the patients as distressing and many were anxious during the treatment. Both the disease and its treatment can disrupt the lives of the woman and adversely affect all aspects of life and thus can alter a woman’s quality of life (QOL)[7, 1015]. Akin et al.,[16] demonstrated that the adverse effects of different cancer or treatment-related symptoms and types of treatment have some correlations with QOL. Furthermore, decreased health-related QOL may affect daily life in patients with breast cancer[17].

                Virgin coconut oil (VCO) is a traditional product that has a long history of ethnopharmacological use. VCO is extracted from fresh coconut flesh at low temperature and without the use of chemicals. Studies have shown that coconut oil inhibits the induction of carcinogenic agents in the colon and in mammary tumours in test animals[1820]. In chemically induced cancers of the colon and breast, coconut oil was shown to be more protective than unsaturated oil. Coconut oil which is rich in medium chain fatty acids, and ideal for immune suppressed individuals. For this reason, it is being studied as a treatment for HIV/AIDS patients whose immune systems are severely compromised[21]. In a clinical study conducted by Soerjodibroto[22] of the effects of VCO on immune responses among HIV positive patients, he concluded that the macronutrient intake, mostly in terms of energy, fats and protein were significantly improved among the VCO supplemented group compared to the control group. In addition, the weight and nutritional status of the subjects, especially among the VCO-supplemented group, were maintained well throughout the study.

                To date, studies on the use of VCO as a dietary supplement in the treatment of cancer patients to improve their QOL are limited. However, this information could help healthcare professionals care for cancer patients and help them maintain a good QOL during treatment. Thus, the purpose of this study was to empirically evaluate the effect of VCO supplementation on the QOL of breast cancer patients undergoing chemotherapy in Kelantan, Malaysia.

                Methods

                Study design

                This was a prospective study of health-related QOL of breast cancer patients. The study was conducted in the Hospital Universiti Sains Malaysia (HUSM) located in Kelantan, Malaysia. HUSM is a tertiary and teaching hospital in Malaysia. The sixty participants included in this study were women ≥ 18 years old who were diagnosed with stage III or IV breast cancer and who underwent six cycles of first-line chemotherapy.

                Pre-assessment using the study instrument was conducted among patients who met the study inclusion criteria during their first visit for their first cycle of chemotherapy. During their second cycle of chemotherapy, patients were randomly assigned to either the intervention or control group using a simple random sampling. Patients in the intervention group (n = 30) were given VCO (10 ml twice daily) as a supplement after 1 week each chemotherapy cycle from the third until the sixth cycle, whereas patients in the control group did not receive any supplement.

                Ethical approval for the study was obtained from the Human Research Ethics Committee, USM and the Director of HUSM. The patients were informed about the study and the informed consent was obtained from the patients.

                Outcome measures

                QOL was measured using the translated Bahasa Malaysia version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (EORTC QLQ-C30) and the Breast Cancer Supplementary Measure (QLQ-BR23) questionnaire. The psychometric properties of the translated version for both questionnaires have been well documented[23, 24].

                The EORTC QLQ-C30 is a well-known instrument for measuring QOL in cancer patients. It contains 30 items that measure the following three main domains: global health status, functional status, and cancer-related symptom status. The QLQ-BR23 is a breast cancer-specific set of 23 questions for assessing functional status and symptoms related to breast cancer. The EORTC raw score of a participant’s responses is transformed according to the EORTC scoring manual[25] into a score ranging from 0 to 100, with a higher score indicating better QOL for functioning and global QOL. For cancer-specific symptoms, a higher score indicates more or worse symptoms and thus a poorer QOL.

                Socio-demographic data collected in this study include age, ethnicity, education level, occupation, household income, marital status, number of children, breastfeeding history, and family history. Clinical data consisting of disease stage and comorbidity were extracted from the participants’ medical records. The patients were interviewed at five time points (first, third, fourth, fifth, and sixth visits) during the six-course therapy cycle. Data were collected personally via interview by the researcher. Time to complete the questionnaire was approximately 15–20 minutes.

                Analysis

                Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 18. Descriptive statistics were used to summarize the patients’ sociodemographic data, and differences between the characteristics of the intervention and control groups were evaluated using the chi square test. The effect of VCO consumption on QOL was determined by calculating the mean score difference between the intervention and control groups. An independent t-test was used to compare the QOL domains score between the intervention and control groups. P ≤ 0.01 was considered to be statistically significant.

                Results

                Characteristics of the study group

                A total of 68 women who were diagnosed with stage III or IV breast cancer were asked to participate in this study. Sixty women (88.2%) completed the entire assessment process from the first cycle of chemotherapy to the sixth cycle. Five women (7.3%) withdrew from the intervention group because they were unable to take VCO, and three (4.5%) women from the control group refused to participate in the study because they were not feeling well. The final intervention group consisted of 30 women, and the control group consisted of 30 women. Characteristics of both the intervention and control groups are presented in Table 1. The age of the intervention group ranged from 31–73 years (mean 47.10 years), and those in the control group ranged in age from 30 to 64 years (mean 49.90 years). The majority of the patients were Malay (intervention group, 96.7%; control group, 80%) and had a secondary level of education (intervention group, 53.3%; control group, 36.7%). In the intervention group, 46.7% of participants were housewives, whereas in the control group 46.7% of participants were civil servants. Most participants had an income ranging between RM 1000 and 3000. Ninety percent of subjects in the intervention group were married compared to 83.3% in the control group. In both groups, 93.3% of patients breastfed their children. In the intervention and control groups, 40% and 20% of subjects, respectively, had a family history of cancer. Statistically, there were no significant differences between the intervention and control groups in terms of their demographic data (Table 1).
                Table 1

                Sociodemographic data and clinical characteristics of the study sample (n = 60)

                Variables

                Frequency (%)

                P*

                Intervention group (n = 30)

                Control group (n = 30)

                Age group (years)

                  

                0.386

                < 40

                6 (19.4)

                9 (29.3)

                40–50

                14 (48.3)

                9 (29.3)

                > 50

                10 (32.3)

                12 (41.4)

                Mean (SD)

                47.10 ( 8.2)

                49.90 (11.5)

                Range

                31–73

                30–64

                Race

                  

                0.097

                Malays

                29 (96.7)

                24 (80.0)

                Chinese

                1 (3.3)

                4 (13.3)

                Indian

                2 ( 6.7)

                Educational level

                  

                0.131

                None

                3 (10.0)

                Primary

                4 (13.3)

                7 (23.3)

                Secondary

                16 (53.3)

                11 (36.7)

                College/University

                10 (33.3)

                9 (30.0)

                Occupation

                  

                0.694

                Housewife

                14 (46.7)

                12 (40.0)

                Civil servant

                13 (43.3)

                14 (46.7)

                Private sector

                3 (10.0)

                4 (13.3)

                Income

                  

                0.209

                < RM 1000

                3 (10.0)

                9 (30.0)

                RM 1000- RM3000

                17 (56.7)

                10 (33.3)

                > RM3000

                10 (33.3)

                11 (36.7)

                Marital status

                  

                0.385

                Single

                1 (3.3)

                1 (3.3)

                Married

                27 (90.0)

                25 (83.3)

                Divorced

                1 (3.3)

                Widowed

                1 (3.3)

                4 (13.3)

                Number of children

                  

                0.131

                < 5

                25 (83.2)

                26 (86.7)

                > 5

                5 (16.8)

                4 (13.3)

                Breast feeding

                  

                0.945

                No

                2 (6.7)

                2 (6.7)

                Yes

                28 (93.3)

                28 (93.3)

                Family history of cancer

                  

                0.128

                No

                18 (60.0)

                24 (80.0)

                Yes

                12 (40.0)

                6 (20.0)

                *Pearson chi square test.

                Functioning and global QOL

                Table 2 shows patients’ functioning and global QOL as measured by the EORTC QLQ-C30. All aspects of functioning showed improvement over time, and every functioning item had higher values in the intervention group compared to the control group at last chemotherapy cycle. Significant differences in mean functioning and global QOL scores between the intervention and control groups were also detected. At the sixth cycle of chemotherapy for global QOL has shown a significant different with a P value < 0.01 (t- stat: 3.325). It can be proven where the difference of the mean score for global quality of life at sixth chemotherapy cycle for the intervention group was 72.03 (SD: 12.81) while the control group was 60.34 (SD: 20.36). These results show more improvement in the intervention group than in the control group when comparing the mean score from the pre-assessment (first cycle) to the post-assessment (sixth cycle).
                Table 2

                Breast cancer patients’ functioning and global quality of life scores as measured by the EORTC QLQ-C30* (n = 60, 30 in each group)

                Functioning

                1st Chemotherapy cycle mean score (SD)

                3rd Chemotherapy cycle mean score (SD)

                4th Chemotherapy cycle mean score (SD)

                5th Chemotherapy cycle mean score (SD)

                6th Chemotherapy cycle mean score (SD)

                 

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Physical

                69.69

                73.57

                68.72

                68.72

                70.53

                75.18

                78.12

                74.48

                83.00

                75.18

                (18.42)

                (27.11)

                (16.39)

                (18.81)

                (16.23)

                (15.00)

                (12.40)

                (19.28)

                (12.17)

                (15.93)

                Role

                58.05

                67.35

                60.77

                59.19

                60.76

                67.25

                69.21

                64.96

                77.98**

                62.09**

                (25.06)

                (35.99)

                (22.19)

                (30.41)

                (21.35)

                (20.16)

                (17.54)

                (19.07)

                (19.42)

                (22.67)

                Emotional

                60.77

                60.77

                62.93

                64.36

                66.09

                66.12

                71.23

                65.81

                76.09**

                62.30**

                (20.35)

                (29.78)

                (14.87)

                (26.72)

                (15.53)

                (21.12)

                (15.52)

                (19.59)

                (14.86)

                (20.92)

                Cognitive

                61.84

                72.99

                72.31

                73.56

                69.35

                70.69

                73.11

                65.52

                80.65**

                64.37**

                (25.12)

                (24.96)

                (18.64)

                (19.68)

                (19.28)

                (25.06)

                (13.38)

                (23.12)

                (15.56)

                (26.62)

                Social

                66.67

                67.44

                66.16

                67.41

                69.37

                68.76

                73.16

                63.04

                77.43

                63.03

                (27.90)

                (31.03)

                (22.93)

                (28.70)

                (23.21)

                (20.48)

                (19.99)

                (21.68)

                (20.43)

                (24.90)

                Global

                51.60**

                65.79**

                55.64**

                71.54**

                61.84

                63.50

                74.21

                67.53

                72.03**

                60.34**

                (13.86)

                (18.95)

                (17.40)

                (16.88)

                (15.19)

                (18.29)

                (54.86)

                (13.96)

                (12.82)

                (20.36)

                *A higher value indicates a higher level of functioning and quality of life: min: 0, max: 100.

                **Significant difference between intervention and control groups, P <0.01;

                Independent t- test.

                Symptoms

                For the symptoms measured using the EORTC QLQ-C30, there were no significant differences in mean symptom scores between the two groups at any cycle of the assessment (Table 3). However, by comparing mean score between the intervention group and the control group in the pre-assessment time point for all symptoms, the intervention group has indicates of a higher mean compared to the control group. Loss of appetite was the most detrimental symptom affecting the QOL for both groups. At the pre-assessment time point, the intervention group had a higher mean score for this symptom (50.53, SD: 33.20) compared to the control group (33.35, SD: 30.88). In addition, fatigue, dyspnea, and sleep difficulties were also lower at sixth cycle of chemotherapy as compared to the first cycle assessment in the intervention group. These results indicate that the QOL increased as the mean score of symptoms decreased.
                Table 3

                Breast cancer patients’ symptoms scores as measured by the EORTC QLQ-C30* (n = 60, 30 in each group)

                Symptom

                1st Chemotherapy cycle mean score (SD)

                3rd Chemotherapy cycle mean score (SD)

                4th Chemotherapy cycle mean score (SD)

                5th Chemotherapy cycle mean score (SD)

                6th Chemotherapy cycle mean score (SD)

                 

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Fatigue

                49.34

                36.38

                44.26

                39.93

                46.06

                40.56

                45.44

                41.71

                45.88

                47.26

                (22.75)

                (24.50)

                (11.69)

                (22.94)

                (13.77)

                (15.76)

                (15.29)

                (15.59)

                (16.10)

                (17.58)

                Nausea and vomiting

                31.19

                24.13

                36.03

                28.73

                30.10

                26.55

                30.11

                33.91

                30.64

                39.08

                (25.38)

                (25.03)

                (24.02)

                (28.48)

                (18.95)

                (20.53)

                (20.82)

                (23.35)

                (21.98)

                (31.89)

                Pain

                34.03

                28.16

                34.97

                29.87

                37.09

                29.30

                34.40

                64.35

                34.94

                41.95

                (23.34)

                (26.39)

                (16.86)

                (21.07)

                (17.05)

                (21.66)

                (18.72)

                (148.92)

                (20.35)

                (20.72)

                Dyspnoea

                22.57

                14.94

                21.51

                12.63

                11.49

                15.58

                18.82

                19.53

                18.29

                20.68

                (26.37)

                (23.30)

                (25.17)

                (18.71)

                (18.72)

                (18.41)

                (23.88)

                (22.74)

                (25.61)

                (24.26)

                Sleep difficulties

                36.55

                24.12

                38.73

                26.42

                37.09

                33.32

                33.86

                35.61

                31.71

                39.06

                (26.33)

                (30.73)

                (24.50)

                (27.29)

                (22.67)

                (28.18)

                (22.16)

                (23.47)

                (25.23)

                (21.96)

                Loss of appetite

                50.53

                33.35

                49.47

                44.25

                48.91

                43.68

                41.38

                43.66

                40.85

                44.82

                (33.20)

                (30.88)

                (27.05)

                (31.60)

                (19.72)

                (25.38)

                (23.14)

                (23.76)

                (23.52)

                (32.47)

                Constipation

                31.16

                28.75

                37.64

                25.28

                38.16

                24.14

                38.70

                34.47

                40.86

                41.38

                (27.12)

                (35.34)

                (23.38)

                (27.69)

                (19.83)

                (28.05)

                (24.50)

                (30.20)

                (26.83)

                (31.71)

                Diarrhoea

                12.90

                10.34

                17.22

                11.49

                17.19

                16.09

                19.34

                17.23

                26.86

                20.69

                (20.50)

                (20.13)

                (22.57)

                (20.46)

                (20.84)

                (22.92)

                (22.39)

                (22.92)

                (59.83)

                (27.34)

                Financial difficulties

                32.25

                26.43

                25.81

                28.73

                33.33

                27.58

                36.56

                31.02

                37.62

                34.48

                (31.61)

                (30.06)

                (25.40)

                (31.78)

                (31.04)

                (30.95)

                (29.01)

                (29.46)

                (29.50)

                (31.48)

                *A higher value indicates a higher level of functioning and quality of life: min: 0, max: 100.

                **Significant different significant difference between intervention and control groups, P < 0.01;

                Independent t- test.

                Breast-specific scores

                The QOL scores for breast cancer patients measured by the EORTC QLQ-BR23 are shown in Table 4. Except for sexual enjoyment, improvements were seen in all other functioning scores (i.e., body image, sexual function and future perspective) compared to the first cycle of chemotherapy in the intervention group. The mean score for sexual function improved in the intervention group between the first and the sixth cycle, but unfortunately, the mean differences were not significant between groups (P > 0.01; t- stat: -1.507). At the fifth chemotherapy cycle, the intervention group had a higher mean score for sexual function compared to the control group (53.83, SD: 27.58 vs. 38.54, SD: 34.04). For symptom status, none of the symptoms (P > 0.01) has shown significant mean score differences between groups at any cycles of the chemotherapy. By comparing between the mean score for intervention group of each symptoms, the symptom of breast (15.59, SD: 17.58 vs 15.08, SD: 12.61) and systematic therapy side effects (38.80, SD: 19.99 vs 38.24, SD: 18.83) has indicate lower mean score at the sixth cycle prior to the first cycle. The side effects of systemic therapy in the control group had the highest mean score of symptoms, which could diminish the QOL among breast cancer patients. Although the score for upset by hair loss was somewhat higher in the intervention group than the control group after six cycles of chemotherapy, the difference between the groups was not statistically significant.
                Table 4

                Breast cancer patients’ functioning and symptoms scores as measured by the EORTC QLQBR23 (n = 60, 30 in each group)

                 

                1st Chemotherapy cycle mean score (SD)

                3rd Chemotherapy cycle mean score (SD)

                4th Chemotherapy cycle mean score (SD)

                5th Chemotherapy cycle mean score (SD)

                6th Chemotherapy cycle mean score (SD)

                 

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Intervention

                Control

                Functioning*

                Body image

                64.52

                73.93

                67.75

                68.70

                67.18

                75.02

                72.66

                71.75

                75.59

                68.72

                (21.71)

                (23.25)

                (18.24)

                (24.24)

                (19.87)

                (17.71)

                (21.16)

                (18.23)

                (24.81)

                (18.91)

                Sexual functioning

                46.82

                33.83

                47.37

                32.16

                54.90

                39.09

                53.83

                38.54

                53.85

                42.55

                (31.23)

                (35.49)

                (30.26)

                (28.93)

                (28.97)

                (31.96)

                (27.58)

                (34.04)

                (28.85)

                (34.17)

                Sexual enjoyment

                34.43

                27.59

                25.85

                19.55

                19.33

                24.14

                22.60

                25.28

                20.44

                27.59

                (32.86)

                (37.91)

                (29.58)

                (30.31)

                (25.55)

                (30.81)

                (29.14)

                (30.49)

                (28.21)

                (31.04)

                Future perspective

                31.08

                48.28

                37.53

                48.31

                37.58

                48.35

                50.60

                50.69

                53.90

                56.48

                (24.30)

                (36.37)

                (25.54)

                (35.27)

                (22.49)

                (29.14)

                (25.80)

                (29.18)

                (22.42)

                (25.51)

                Symptom+

                Arm

                24.72

                17.99

                25.43

                19.53

                27.23

                24.51

                27.94

                22.97

                27.94

                24.88

                (22.72)

                (18.39)

                (17.73)

                (21.13)

                (20.86)

                (22.29)

                (17.42)

                (16.51)

                (18.35)

                (17.97)

                Breast

                15.59

                12.55

                10.74

                14.88

                10.21

                18.10

                13.71

                16.37

                15.04

                20.68

                (17.58)

                (18.71)

                (11.82)

                (19.08)

                (8.26)

                (18.38)

                (9.76)

                (12.09)

                (12.61)

                (16.75)

                Systematic therapy side effect

                38.80

                33.18

                39.02

                37.29

                39.79

                39.91

                42.10

                41.20

                38.24

                48.65

                (19.99)

                (16.77)

                (14.73)

                (16.87)

                (13.99)

                (19.25)

                (17.99)

                (19.68)

                (18.83)

                (18.23)

                Upset by hair loss

                25.28

                31.03

                24.51

                16.67

                34.48

                25.28

                34.84

                28.96

                36.77

                36.77

                (30.13)

                (36.42)

                (24.73)

                (27.46)

                (31.48)

                (31.70)

                (24.45)

                (30.31)

                (28.82)

                (31.31)

                *Scores range from 0 to 100, with higher scores representing a higher level of functioning.

                +Scores range from 0 to 100, with higher scores representing a higher level of symptoms.

                **Significant different, P <0.01;

                Discussion

                This study was designed to evaluate the effectiveness of VCO on the QOL of patients with breast cancer throughout six cycles of chemotherapy. The results showed that the functional status and global QOL were improved in the intervention group, with significant mean score differences between groups. Additionally, symptoms of fatigue, dyspnea, sleep difficulties and loss of appetite were also decreased in the intervention group, measured at the sixth cycle of chemotherapy. For breast-specific scores, there was improvement in all other patients’ functioning scores likes body image, sexual function and future perspective. Breast symptoms and side effects of systemic therapy showed significant mean score differences between groups at the sixth cycle of chemotherapy.

                The findings of this study showed that women had a satisfactory score on functioning and global quality of life after consumption of VCO. In fact, breast cancer and its treatment, especially chemotherapy, can disrupt the QOL of breast cancer patients[12, 13, 26]. In addition, a study done by Vardy[15] & Lemieux et al.,[27] reported that quality of life was most affected after patients experienced side effects from breast cancer treatments. At the sixth chemotherapy cycle, mean score for global QOL for the intervention group was 72.03 (SD: 12.82) while the control group was only 60.34 (SD: 20.36). This finding is contrary to the study performed by Montazeri et al.,[28], whereby the global health score was reduced. Nevertheless, the results are similar to Costanzo et al.,[29], which showed improvement in physical functioning. It is believed that consumption of VCO helped in increasing the energy level as well as maintaining physical function among the breast cancer patients. The effects of VCO in terms of energy, fats and protein metabolism have been demonstrated in the study carried out by Soerjodibroto[22]. The study highlighted that VCO had a positive effect on immune responses among HIV positive patients which showed improvements and maintained stable throughout the study. Lauric acid which is a disease- fighting substance that has many health benefits[3032], is abundant in coconut oil. Fife[33] also mentioned that coconut oil improves nutrient absorption, boosts energy, possesses potent antimicrobial properties, and improves energy metabolism in the brain. There have been emerging fundamental evidences to explain the positive clinical effects of VCO on human health.

                For the symptom scores evaluated in this study, no significant differences between the two groups were detected. Thus, the improvement of the symptoms scores were presented such as fatigue, dyspnea, sleep difficulties and loss of appetite at the sixth chemotherapy cycle. Serious side effects of chemotherapy often are perceived by patients as distress factors that contribute to poor QOL[12, 26]. For example, the most commonly reported symptom that affects QOL was loss of appetite. During the pre-assessment, the intervention group had a higher mean score for this symptom (50.53, SD: 33.20) than the control group (33.35, SD: 30.88). However, after VCO supplementation, the mean score of the intervention group declined and no significant difference between the two groups was detected. Coconut oil is unique, known as medium-chain triglycerides that are usually used to improve patients’ nutritional status[32, 33]. In addition, maintaining a good appetite can promote wound healing and encourage a speedy recovery from illness[7].

                The QOL scores of breast cancer patients as measured by the EORTC QLQ-BR23 in this study showed improvement in several measures of function such as body image, future perspective and sexual function in the intervention group. Compared to a study performed by Montazeri et al.,[34], instead use found that most of the function mean scores decreased especially sexual function as a result of premature menopause following adjuvant systemic therapy in breast cancer patients. Physical and emotional status have been shown to affect sexuality, including negative body image, feelings of sexual unattractiveness, loss of femininity, depression, and anxiety following breast cancer diagnosis[35]. Ganz et al.,[36] found that sexual functioning was worse for women who received chemotherapy. A similar result has been noted in another study from University of Sto. Tomas unveiled the beneficial effects of VCO on health and sex life. 13% of the VCO takers (189 participants) experienced becoming sexually active in the whole duration of their participation in the VCO study[37].

                The current study was limited by the small number of breast cancer patients in Kelantan, Malaysia. Therefore, a large, multi-state comparison with varying demographics should be conducted in Malaysia. Furthermore, additional VCO intervention studies should be performed to confirm the specific beneficial effects of VCO that were detected in this study.

                Conclusion

                This study revealed improved functional and global QOL of breast cancer patients who consumed VCO during the six cycle chemotherapy treatment and showed significant differences in functional and global QOL between the intervention and control groups. VCO may help in promoting the functional and global QOL of breast cancer patients who are undergoing chemotherapy. These results also suggest that VCO consumption could reduce the women’s symptoms and improve several items of functional status such as body image, future perspective and sexual function. Based on the results, there are certainly good prospect of utilizing VCO as supplementation among breast cancer patients towards achieving a positive QOL.

                Declarations

                Acknowledgements

                The authors would like to thank all the women who have generously given their time to be involved in this study. We would also like to acknowledge that the funding of this research project was supported by a USM short-term grant:304/CIPPT/6311075. Also, we would like to extend our heartfelt gratitude to Hospital Universiti Sains Malaysia for their permission to conduct this study.

                Authors’ Affiliations

                (1)
                Institut Perubatan dan Pergigian Termaju, Universiti Sains Malaysia, Bertam
                (2)
                School of Medical Science, Health Campus, Universiti Sains Malaysia

                References

                1. Wahid MI: Breast Cancer.http://​www.​malaysiaoncology​.​org/​article.​php?​aid=​114,
                2. Lim CC, Rampal S, Halimah Y: Cancer Incidence in Peninsular Malaysia, 2003–2005.http://​www.​moh.​gov.​my/​images/​gallery/​Report/​Cancer/​CancerIncidencei​nPeninsularMalay​sia2003-2005x1x.​pdf,
                3. Nur Aishah MT, Cheng HY, Mohamed I: Survival analysis of Malaysian women with breast cancer: results from the University of Malaya Medical Centre. Asian Pac J Cancer Prev. 2008, 9: 197-202.
                4. Kwan ML, Ergas IJ, Somkin CP, Quesenberry CP, Neugut AI, Hershman DL, Mandelblatt J, Pelayo MP, Timeri AW, Mies SQ, Ksh LH: Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study. Breast Cancer Res Treat. 2010, 23 (2): 507-524.View Article
                5. Hayes SC, Rye S, Battistutta D, DiSipio T, Newman B: Upper-body morbidity following breast cancer treatment is common, may persist longer-term and adversely influences quality of life. Health Qual Life Outcomes. 2010, 8: 92-98. 10.1186/1477-7525-8-92PubMed CentralView ArticlePubMed
                6. Carling M, Goodare H, Ironside A, Millington J, Rogers C: Quality of life after breast radiotherapy. Lancet Oncol. 2010, 11 (7): 612-613.View ArticlePubMed
                7. Lua PL, Zakaria NS, Mamat NM: Health-related quality of life profile in relation to chemotherapy-induced nausea and vomiting among breast cancer patients. ASEAN J Psyhiatry. 2012, 13: 1-
                8. Jim HS, Andrykowski MA, Munster PN, Jacobsen PB: Physical symptoms/side effects during breast cancer treatment predict posttreatment distress. Ann Behav Med. 2007, 34 (2): 200-208. 10.1007/BF02872674View ArticlePubMed
                9. Bergkvist K, Wengstrom Y: Symptom experiences during chemotherapy treatment with focus on nausea and vomiting. Eur J Oncol Nurs. 2006, 10: 21-29.View ArticlePubMed
                10. Frost MH, Suman VJ, Rummans TA, Dose AM, Taylor M, Novotny P, Johnson R, Evans RE: Physical, psychological and social well-being of women with breast cancer: the influence of disease phase. Psychooncology. 2000, 9: 22-31.
                11. Schnipper HH: Life after breast cancer. J Clin Oncol. 2001, 19 (15): 3581-3584.PubMed
                12. Mulders M, Vingerhoets A, Breed W: The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs. 2008, 12: 91-102.View Article
                13. Montazeri A: Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008, 27: 32- 10.1186/1756-9966-27-32PubMed CentralView ArticlePubMed
                14. Salonen P, Tarkka MT, Kellokumpu-Lehtinen PL, Astedt-Kurki P, Luukkaala T, Kaunonen M: Telephone intervention and quality of life in patients with breast cancer. Cancer Nurs. 2009, 32 (3): 177-190. 10.1097/NCC.0b013e31819b5b65View ArticlePubMed
                15. Vardy J: Cognitive function in breast cancer survivors. Cancer Treat Res. 2009, 151: 387-419. 10.1007/978-0-387-75115-3_24View ArticlePubMed
                16. Akin S, Can G, Durna Z, Aydiner A: The quality of life and self-efficacy of Turkish breast cancer patients undergoing chemotherapy. Eur J Oncol Nurs. 2008, 12 (5): 449-456. 10.1016/j.ejon.2008.07.006View ArticlePubMed
                17. Richardson LC, Wang W, Hartzema AG, Wagner S: The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J. 2007, 13: 581-587. 10.1111/j.1524-4741.2007.00512.xView ArticlePubMed
                18. Reddy BS, Maeura Y: Tumor promotion of dietary fat in azoxymethane-induced colon carcinogenesis in female F 344 rats. J Natl Cancer Inst. 1984, 72: 745-750.PubMed
                19. Cohen LA, Thompson DO, Maeura Y, Choi K, Blank ME, Rose DP: Dietary fat and mammary cancer. Promoting effects of different dietary fats on N-nitrosomethylurea- induced rat mammary tumorigenesis. J Natl Cancer Inst. 1986, 77 (1): 33-42.PubMed
                20. Virgin coconut oil “Miracle cure for cancer”. [http://​www.​thevirgincoconut​oil.​com/​articleitem.​php?​articleid=​176], []
                21. Dayrit CS: Coconut Oil in Health and Disease: Its and Monolaurin’s Potential as Cure for HIV-AIDS. [http://​www.​coconutresearchc​enter.​org/​article10526.​pdf], []
                22. Soerjodibroto W: Research Report on the Effects of Virgin Coconut Oil on Immune Responses among HIV Positive Patients in Dharmais Hospital, Jakarta. 2006,
                23. Yusoff N, Low WY, Yip CH: The Malay version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ C30): realibility and validity study. Int Med J Malays. 2010, 9 (2): 45-50.
                24. Yusoff N, Low W, Yip C: Psychometric properties of the Malay version of the Breast Module (BR23). Singapore Med J. 2012, 53 (1): 36-PubMed
                25. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, : EORTC QLQ-C30 Scoring Manual. 2001, Brussels: EORTC, 3,
                26. Yusuf A, Ahmad Z, Keng SL: Quality of life inMalays and Chinese women newly diagnosed with breast cancer in Kelantan, Malaysia. Asian Pac J Cancer Prev. 2013, 14 (1): 435-440. 10.7314/APJCP.2013.14.1.435View ArticlePubMed
                27. Lemieux J, Maunsell E, Provencher L: Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology. 2008, 17 (4): 317-328. 10.1002/pon.1245View ArticlePubMed
                28. Montazeri A, Vahdaninia M, Harirchi I, Ebrahimi M, Khaleghi F, Jarvandi S: Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer. 2008, 8: 330- 10.1186/1471-2407-8-330PubMed CentralView ArticlePubMed
                29. Costanzo ES, Lutgendorf SK, Mattes ML, Trehan S, Robinson CB, Tewfik F, Roman SL: Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. Br J Cancer. 2007, 97: 1625-1631. 10.1038/sj.bjc.6604091PubMed CentralView ArticlePubMed
                30. Enig MG: Coconut Oil: An Anti-bacterial, Anti-viral ingredient for Food, Nutrition and Health. 1997, Manila, Philippines: AVOC Lauric Symposium,
                31. Rubin J: Extra virgin coconut oil –the good saturated fat. Total Health. 2003, 25: 3-
                32. Marina AM, YB C m, Nazimah SAH, Amin I: Antioxidant capacity and phenolic acids of virgin coconut oil. Int J Food Sci Nutr. 2009, 60 (2): 114-123.View ArticlePubMed
                33. Fife B: Health properties of coconut oils.http://​coconutresearchc​enter.​org/​Health%20​Properties%20​of%20​Coconut%20​Oil-Fife.​pdf,
                34. Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S, Ebrahimi M: The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): Translation and validation study of the Iranian version. Qual Life Res. 2000, 9: 177-184. 10.1023/A:1008918310251View ArticlePubMed
                35. Emilee G, Ussher JM, Perz J: Sexuality after breast cancer: a review. Maturitas. 2010, 66: 397-407. 10.1016/j.maturitas.2010.03.027View ArticlePubMed
                36. Ganz PA, Kwan L, Stanton AL: Quality of Life at the end of primary treatment of breast cancer: First results from the Moving Beyond Cancer randomized trial. J Natl Cancer Inst. 2004, 96 (5): 376-387. 10.1093/jnci/djh060View ArticlePubMed
                37. Binag C: Virgin Coco Oil Great For Sex And Cholesterol Ust Study.http://​www.​gmanetwork.​com/​news/​story/​249878/​scitech/​science/​virgin-coco-oil-great-for-sex-and-cholesterol-ust-study,

                Copyright

                © Law et al.; licensee BioMed Central Ltd. 2014

                This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

                Advertisement